Terms: = Skin cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
33 results:
1. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
2. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
3. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract] [Full Text] [Related]
4. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract] [Full Text] [Related]
5. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
Mantia CM; Werner L; Stwalley B; Ritchings C; Tarhini AA; Atkins MB; McDermott DF; Regan MM
Melanoma Res; 2022 Feb; 32(1):35-44. PubMed ID: 34855329
[TBL] [Abstract] [Full Text] [Related]
6. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Robert C; Hwu WJ; Hamid O; Ribas A; Weber JS; Daud AI; Hodi FS; Wolchok JD; Mitchell TC; Hersey P; Dronca R; Joseph RW; Boutros C; Min L; Long GV; Schachter J; Puzanov I; Dummer R; Lin J; Ibrahim N; Diede SJ; Carlino MS; Joshua AM
Eur J Cancer; 2021 Feb; 144():182-191. PubMed ID: 33360855
[TBL] [Abstract] [Full Text] [Related]
7. MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.
Chen A; Santana AL; Doudican N; Roudiani N; Laursen K; Therrien JP; Lee J; Felsen D; Carucci JA
PLoS One; 2020; 15(11):e0241551. PubMed ID: 33227008
[TBL] [Abstract] [Full Text] [Related]
8. Biomarkers Associated with clinical outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
[TBL] [Abstract] [Full Text] [Related]
9. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract] [Full Text] [Related]
10. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict clinical outcome.
Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
[No Abstract] [Full Text] [Related]
11. Tracking the Evolution of Non-Small-Cell Lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.
Miller NJ; Church CD; Dong L; Crispin D; Fitzgibbon MP; Lachance K; Jing L; Shinohara M; Gavvovidis I; Willimsky G; McIntosh M; Blankenstein T; Koelle DM; Nghiem P
Cancer Immunol Res; 2017 Feb; 5(2):137-147. PubMed ID: 28093446
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
[TBL] [Abstract] [Full Text] [Related]
14. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract] [Full Text] [Related]
15. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
Yuan J; Zhou J; Dong Z; Tandon S; Kuk D; Panageas KS; Wong P; Wu X; Naidoo J; Page DB; Wolchok JD; Hodi FS
Cancer Immunol Res; 2014 Feb; 2(2):127-32. PubMed ID: 24778276
[TBL] [Abstract] [Full Text] [Related]
16. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
Beale S; Dickson R; Bagust A; Blundell M; Dundar Y; Boland A; Marshall E; Plummer R; Proudlove C
Pharmacoeconomics; 2013 Dec; 31(12):1121-9. PubMed ID: 24114739
[TBL] [Abstract] [Full Text] [Related]
17. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.
Finocchiaro LM; Glikin GC
Cancer Gene Ther; 2012 Dec; 19(12):852-61. PubMed ID: 23059870
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide association study identifies new prostate cancer susceptibility loci.
Schumacher FR; Berndt SI; Siddiq A; Jacobs KB; Wang Z; Lindstrom S; Stevens VL; Chen C; Mondul AM; Travis RC; Stram DO; Eeles RA; Easton DF; Giles G; Hopper JL; Neal DE; Hamdy FC; Donovan JL; Muir K; Al Olama AA; Kote-Jarai Z; Guy M; Severi G; Grönberg H; Isaacs WB; Karlsson R; Wiklund F; Xu J; Allen NE; Andriole GL; Barricarte A; Boeing H; Bueno-de-Mesquita HB; Crawford ED; Diver WR; Gonzalez CA; Gaziano JM; Giovannucci EL; Johansson M; Le Marchand L; Ma J; Sieri S; Stattin P; Stampfer MJ; Tjonneland A; Vineis P; Virtamo J; Vogel U; Weinstein SJ; Yeager M; Thun MJ; Kolonel LN; Henderson BE; Albanes D; Hayes RB; Feigelson HS; Riboli E; Hunter DJ; Chanock SJ; Haiman CA; Kraft P
Hum Mol Genet; 2011 Oct; 20(19):3867-75. PubMed ID: 21743057
[TBL] [Abstract] [Full Text] [Related]
20. Long-term outcome of Spitz-type melanocytic tumors.
Sepehr A; Chao E; Trefrey B; Blackford A; Duncan LM; Flotte TJ; Sober A; Mihm MC; Tsao H
Arch Dermatol; 2011 Oct; 147(10):1173-9. PubMed ID: 21680758
[TBL] [Abstract] [Full Text] [Related]
[Next]
